Kurzfassung

A randomized, double-blind, multicenter study to assess the efficacy and safety of 16 weeks secukinumab dosage interval shortening (2-weekly 300 mg s.c.) in comparison to continued standard treatment (4-weekly 300 mg s.c.) in patients with moderate-severe plaque type psoriasis who achieved less than clear or almost clear skin (PASI response 75 to PASI<90) after 16 weeks under the standard dose of secukinumab